Literature DB >> 28129456

Oral squamous cell carcinoma in the background of oral submucous fibrosis is a distinct clinicopathological entity with better prognosis.

Amol Ramchandra Gadbail1, Minal Chaudhary1, Madhuri Gawande1, Alka Hande1, Sachin Sarode2, Satyajit Ashok Tekade3, Sheetal Korde4, Prajakta Zade1, Rahul Bhowate5, Rajiv Borle6, Swati Patil1.   

Abstract

BACKGROUND: The aim of this study was to compare the clinicopathological features of oral squamous cell carcinoma in the background of oral submucous fibrosis (OSCC-OSMF) and oral squamous cell carcinoma (OSCC).
METHODS: A total of 217 cases of OSCC were retrieved from achieves for the analysis. OSCC-OSMF cases were segregated on the basis of history and clinicopathological parameters.
RESULTS: The study included 217 patients of which 112 had OSCC and 105 OSCC-OSMF. OSCC-OSMFs were younger compared with OSCC. Overall oral cancer was noted predominantly in males compared to females. The number of OSCC-OSMF was more in clinical TNM stage I and stage II as compared to OSCC, whereas the number of OSCC was more in stage III and stage IV compared to OSCC-OSMF. Histological presentation of well-differentiated squamous cell carcinoma was significantly more in OSCC-OSMF compared to OSCC, whereas moderately differentiated squamous cell carcinoma was significantly more in OSCC compared to OSCC-OSMF. Regional lymph node metastasis was significantly higher in OSCC compared to OSCC-OSMF. Three-year disease-free survival rate was significantly higher in OSCC-OSMF compared to OSCC.
CONCLUSION: The OSCC-OSMF was found to be a clinicopathologically distinct entity with a better grade of tumor differentiation, less incidence of nodal metastases, and early detection (early clinical TNM stage) compared to OSCC. All these factors probably contribute to a better prognosis and increased 3-year disease-free survival in OSCC-OSMF patients.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  areca nut; oral submucous fibrosis; squamous cell carcinoma; tobacco

Mesh:

Year:  2017        PMID: 28129456     DOI: 10.1111/jop.12553

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  11 in total

Review 1.  Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review.

Authors:  Dr Shailesh M Gondivkar; Dr Amol R Gadbail; Dr Sachin C Sarode; Dr Rima S Gondivkar; Shankargouda Patil; Dr Rahul N Gaikwad; Dr Monal Yuwanati
Journal:  J Oral Biol Craniofac Res       Date:  2020-05-18

Review 2.  Clinical efficacy of mouth exercising devices in oral submucous fibrosis: A systematic review.

Authors:  Shailesh M Gondivkar; Amol R Gadbail; Sachin C Sarode; Rima S Gondivkar; Shankargouda Patil; Rahul N Gaikwad; Monal Yuwanati
Journal:  J Oral Biol Craniofac Res       Date:  2020-07-03

3.  An Evaluation of Clinical and Histopathological Aspects of Patients with Oral Submucous Fibrosis in the Background of Oral Squamous Cell Carcinoma.

Authors:  B S M S Siriwardena; K L T D Jayawardena; N H Senarath; W M Tilakaratne
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

4.  A retrospective study of clinicopathological features of oral squamous cell carcinoma with and without oral submucous fibrosis.

Authors:  Swetha Acharya; Sartaz Rahman; Kaveri Hallikeri
Journal:  J Oral Maxillofac Pathol       Date:  2019 Jan-Apr

5.  Ki67, CD105, and α-SMA Expression Supports Biological Distinctness of Oral Squamous Cell Carcinoma Arising in the Background of Oral Submucous Fibrosis.

Authors:  Amol Ramchandra Gadbail; Sheetal Korde; Minal S Chaudhary; Sachin C Sarode; Shailesh M Gondivkar; Ravi Dande; Satyajit Ashok Tekade; Monal Yuwanati; Alka Hande; Shankargouda Patil
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

6.  Prevalence of Trismus and Its Impact on Oral Health-Related Quality of Life in Patients Treated for Oral Squamous Cell Carcinoma.

Authors:  Shailesh M Gondivkar; Amol R Gadbail; Sachin C Sarode; Subhrajit Dasgupta; Balkrishna Sharma; Amol Hedaoo; Aparna Sharma; Gargi S Sarode; Monal Yuwanati; Rima S Gondivkar; Shankargouda Patil; Rahul N Gaikwad
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

7.  Serum aflatoxin B1 antibody titer, percent hemolysis and transaminases in oral submucous fibrosis.

Authors:  Rahul R Bhowate; Vidya K Lohe; Mrunal Ghusaji Meshram; Suwarna B Dangore
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14

8.  CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma.

Authors:  L-C Silva; F-P Fonseca; O-P Almeida; B-A Mariz; M-A Lopes; R Radhakrishnan; M Sharma; L-P Kowalski; P-A Vargas
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-01-01

9.  Carcinoma Arising in the Background of Oral Submucous Fibrosis.

Authors:  Shruthi Rangaswamy; Rajkumar Garudanahally Chikkalingaiah; Priya N Sanjeevarayappa; Poornima Govindraju
Journal:  Ann Maxillofac Surg       Date:  2019 Jul-Dec

10.  Oral submucous fibrosis stimulates invasion and epithelial-mesenchymal transition in oral squamous cell carcinoma by activating MMP-2 and IGF-IR.

Authors:  Pei-Ni Chen; Chiao-Wen Lin; Shun-Fa Yang; Yu-Chao Chang
Journal:  J Cell Mol Med       Date:  2021-09-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.